Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

MedAlliance, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

MedAlliance, LLC

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name MedAlliance, LLC. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 18, 2026 to Nov 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code OOB appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250041, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 4 Jenner, Suite 190, Irvine, CA, 92618. Recorded on P250041/S001, decision dated Nov 6, 2026.

Changes described in PMA records

P250041/S001: SELUTION SLR 014 PTCA Drug-Eluting Balloon

The FDA recorded an approval decision on 2026-11-06 for P250041/S001, a PMA supplement to the SELUTION SLR™ 014 PTCA Drug-Eluting Balloon (product code OOB, cardiovascular; applicant MedAlliance, LLC). The supplement is listed as a Normal 180 Day Track No User Fee submission with reason Postapproval Study Protocol. This action covers the postapproval study protocol, not a new approval of the underlying device system.

The recorded statement describes the SELUTION4ISR Continued Follow-up Study, which will evaluate long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket SELUTION4ISR study, with annual follow-up through 5 years post-procedure and efforts to minimize missing long-term data. The public documentation contains no documents, so the protocol details, endpoints and any conditions of approval cannot be verified here.

Whether the follow-up study has begun, its enrollment status and any FDA-required milestones are not stated in the available data and remain unknown.

FDA approval-order wording

SELUTION4ISR Continued Follow-up Study will evaluate the long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket study (SELUTION4ISR). Subjects will be followed annually through 5 years post-procedure, and all efforts will be made to minimize the amount of missing long-term data.

Nov 6, 2026 · Normal 180 Day Track No User Fee

P250041: SELUTION SLR 014 PTCA Drug-Eluting Balloon

FDA’s recorded scope: The SELUTION SLR 014 PTCA Drug-Eluting Balloon is intended to be used after appropriate vessel preparation in patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.25 mm to 4.50 mm in diameter and lesions <= 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).

Sep 18, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. SELUTION SLR 014 PTCA Drug-Eluting Balloon

    P250041/S001 · PMA supplement
  2. SELUTION SLR 014 PTCA Drug-Eluting Balloon

    P250041 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.